Print Friendly, PDF & Email

NCT/Study#

NCT02631070 /

ACE-536-MDS-002

A Phase 3, Open-Label, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (ACE-536) Versus Epoetin Alfa For The Treatment Of Anemia Due To IPSS-R Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes (MDS) In ESA Naïve Subjects Who Require Red Blood Cell Transfusions

DISEASE GROUP:
Leukemia
current phase:
Phase III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: